Results 191 to 200 of about 4,936,765 (261)

Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine. [PDF]

Npj Ment Health Res
Janavičius R.
europepmc   +1 more source

Psychological and Neurodevelopmental Correlates of Extreme Demand Avoidance in a Clinical Sample, an Exploratory Study

Autism Research, EarlyView.
ABSTRACT Extreme/pathological demand avoidance (EDA) is a behavioral profile characterized by the avoidance of everyday demands, with significant impact on the individuals and those around them. Little is understood regarding the correlates and drivers of EDA; understanding these better may lead to targeted interventions and support strategies.
Oliver Lack, Matthew J. Hollocks, Gillian Baird, Ann Ozsivadjian, Michael Absoud, Francesca Happé, Emily Simonoff   +6 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

The relocation of a psychiatric crisis intervention unit from a somatic to a psychiatric hospital: a multi-method observational study. [PDF]

Sci Rep
Billian J, Möller J, Imfeld L, Rabenschlag F, Sterzer P, Lang UE, Lieb R, Huber CG.   +7 more
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source